Little is known about the relationship between neighborhood disadvantage and neuromyelitis optica spectrum disorder (NMOSD) outcomes.
Objective:
The objective is to determine the impact of neighborhood disadvantage on time from symptom onset to diagnosis and annualized relapse rate (ARR).
Methods:
Neighborhood disadvantage were captured with the Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage. Negative binomial regression models assessed the impact of ADI on diagnostic delay (⩾3 months between symptom onset and diagnosis) and ARR.
Results:
A total of 158 NMOSD patients were identified, a majority of whom were White (56.3%) and female (89.9%) with a mean age of 46 years at diagnosis. The ADI did not significantly affect odds of diagnostic delay (odds ratio (OR) = 0.99, p = 0.26). In univariable models, the ADI was not significantly associated with ARR (OR = 1.004, p = 0.29), but non-White race (OR = 1.541, p = 0.02) and time on immunosuppressive therapies (ISTs; OR = 0.994, p = 0.03) were. White patients used IST for an average of 81% of the follow-up period, compared to an average of 65% for non-White patients (p < 0.01).
Conclusion:
No significant relationship between neighborhood-level disadvantage and diagnostic delay or ARR in NMOSD patients was observed. Non-White patients had a higher ARR, which may be related to less IST use.
FlanaganEPCabrePWeinshenkerBG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol2016; 79(5): 775–783.
2.
HouzenHKondoKNiinoM, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology2017; 89(19): 1995–2001.
3.
RosendaleN. Social Determinants of health in neurology. Neurol Clin2022; 40(1): 231–247.
4.
AdlerNEGlymourMMFieldingJ. Addressing social determinants of health and health inequalities. JAMA2016; 316(16): 1641–1642.
5.
Gray-RoncalKFitzgeraldKCRyersonLZ, et al. Association of disease severity and socioeconomic status in Black and White Americans with multiple sclerosis. Neurology2021; 97(9): e881–e889.
6.
HardingKEWardleMCarruthersR, et al. Socioeconomic status and disability progression in multiple sclerosis: A multinational study. Neurology2019; 92(13): e1497–e1506.
7.
CalocerFDejardinOKwiatkowskiA, et al. Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients. Mult Scler Relat Disord2020; 40: 101930.
8.
AmezcuaLRiveraVMVazquezTC, et al. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: A Review. JAMA Neurol2021; 78(12): 1515–1524.
9.
KimSHMealyMALevyM, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology2018; 91(22): e2089–e2099.
10.
PalaceJLinDYZengD, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain2019; 142(5): 1310–1323.
11.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85(2): 177–189.
12.
UherTAdzimaASrpovaB, et al. Diagnostic delay of multiple sclerosis: Prevalence, determinants and consequences. Mult Scler2023; 29(11–12): 1437–1451.
13.
GhiasianMFaryadrasMMansourM, et al. Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016. Acta Neurol Belg2021; 121(1): 199–204.
14.
SeokJMChoHJAhnSW, et al. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. Mult Scler2017; 23(13): 1748–1756.
15.
MarrieRAYuBNLeungS, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: Validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler2012; 18(9): 1310–1319.
16.
MarrieRA. Comorbidity in multiple sclerosis: Implications for patient care. Nat Rev Neurol2017; 13(6): 375–382.
17.
LevyMMealyMA. B-Cell targeted treatments for neuromyelitis optica spectrum disorder: A focus on CD19 and CD20. Immunotargets Ther2021; 10: 325–331.
18.
BilodeauPAVishnevetskyAMolazadehN, et al. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler2024; 30(3): 357–368.
19.
KindAJJencksSBrockJ, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: A retrospective cohort study. Ann Intern Med2014; 161(11): 765–774.
20.
HuntJFVVogtNMJonaitisEM, et al. Association of neighborhood context, cognitive decline, and cortical change in an unimpaired cohort. Neurology2021; 96(20): e2500–e2512.
21.
KindAJHBuckinghamWR. Making neighborhood-disadvantage metrics accessible–The neighborhood Atlas. N Engl J Med2018; 378(26): 2456–2458.
DobsonRRiceDRD’HoogheM, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol2022; 18(12): 723–734.
24.
SinghGK. Area deprivation and widening inequalities in US mortality, 1969-1998. Am J Public Health2003; 93(7): 1137–1143.
25.
McEntegartAMorrisonECapellHA, et al. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis1997; 56(7): 410–413.
26.
HarrisonMJTrickerKJDaviesL, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol2005; 32(12): 2330–2336.
27.
ZuijdwijkCSCuerdenMMahmudFH. Social determinants of health on glycemic control in pediatric type 1 diabetes. J Pediatr2013; 162(4): 730–735.
28.
AbbatemarcoJRCarlsonAOntanedaD, et al. Association of socioeconomic disadvantage and neighborhood disparities with clinical outcomes in multiple sclerosis patients. Mult Scler Relat Disord2022; 61: 103734.
29.
VasileiouESFilippatouAGPimentel MaldonadoD, et al. Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis. Brain2021; 144(12): 3664–3673.
30.
NahonSLahmekPMacaigneG, et al. Socioeconomic deprivation does not influence the severity of Crohn’s disease: Results of a prospective multicenter study. Inflamm Bowel Dis2009; 15(4): 594–598.
31.
LublinFDHaringDAGanjgahiH, et al. How patients with multiple sclerosis acquire disability. Brain2022; 145(9): 3147–3161.
32.
WingerchukDMPittockSJLucchinettiCF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology2007; 68(8): 603–605.
33.
KitleyJLeiteMINakashimaI, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain2012; 135(Pt 6): 1834–1849.
34.
PanditLAsgariNApiwattanakulM, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler2015; 21(7): 845–853.
